This Article Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article link to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Muggia, F. Search for Related Content PubMed Articles by Muggia, F.

Section Editor’s Note

Director, Division of Medical Oncology, NYU Medical Center

Seldom do oncologists get an opportunity to read fully referenced presentations of opposing views. Editorials may partly dispute the analysis in an article under review, but they are usually selected to reinforce the importance of a new finding. This issue of The Oncologist provides an in-depth discussion of opposing views concerning the adjuvant therapy of stage II colon cancer. The importance of this subject is further emphasized by it having been the focus of American Society of Clinical Oncology (ASCO) recommendations (Table 1), since it concerns a large number of patients every year that undergo resection for colon cancer. Although the authors of Table 2 argue against adjuvant therapy, the points of discussion between the physician and the patient identify several issues that may, in fact, lead a person (and his or her physician) to be inclined to opt for adjuvant treatment.

This Article Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article link to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Muggia, F. Search for Related Content PubMed Articles by Muggia, F.